AR095427A1 - Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca - Google Patents

Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca

Info

Publication number
AR095427A1
AR095427A1 ARP140100971A ARP140100971A AR095427A1 AR 095427 A1 AR095427 A1 AR 095427A1 AR P140100971 A ARP140100971 A AR P140100971A AR P140100971 A ARP140100971 A AR P140100971A AR 095427 A1 AR095427 A1 AR 095427A1
Authority
AR
Argentina
Prior art keywords
fibrosis
treatment
aromatic compounds
skin
heart
Prior art date
Application number
ARP140100971A
Other languages
English (en)
Inventor
Gagnon Lyne
Laurin Pierre
Grouix Brigitte
Geerts Lilianne
Sarra-Bournet Franois
leduc Martin
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of AR095427A1 publication Critical patent/AR095427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere a compuestos aromáticos sustituidos para utilizar para la prevención o el tratamiento de diversas enfermedades y afecciones fibróticas en los sujetos, incluida la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca, en donde el compuesto tiene la fórmula (1) o una sal farmacéuticamente aceptable de este, en donde A es alquilo C₅, alquilo C₆, alquenilo C₅, alquenilo C₆, C(O)-(CH₂)ₙ-CH₃ o CH(OH)-(CH₂)ₙ-CH₃ en donde n es 3 ó 4; R¹ es H, OH o F; R² es H, OH, F o CH₂-OH; R³ es H, OH, F o CH₂Ph; R⁴ es H, OH o F; Q es i) (CH₂)ₘC(O)OH en donde m es 1 ó 2, ii) CH(CH₃)C(O)OH, iii) C(CH₃)₂C(O)OH, iv) CH(F)-C(O)OH, v) CF₂-C(O)OH o vi) C(O)-C(O)OH.
ARP140100971A 2013-03-15 2014-03-13 Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca AR095427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798427P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095427A1 true AR095427A1 (es) 2015-10-14

Family

ID=51535670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100971A AR095427A1 (es) 2013-03-15 2014-03-13 Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca

Country Status (26)

Country Link
US (3) US9884802B2 (es)
EP (1) EP2970088B1 (es)
JP (1) JP6381557B2 (es)
KR (1) KR102303493B1 (es)
CN (1) CN105143170B (es)
AR (1) AR095427A1 (es)
AU (1) AU2014231649C1 (es)
BR (1) BR112015023129A2 (es)
CA (1) CA2905633C (es)
CL (1) CL2015002725A1 (es)
DK (1) DK2970088T3 (es)
EA (1) EA031511B1 (es)
ES (1) ES2780825T3 (es)
HK (1) HK1220439A1 (es)
IL (1) IL241164B (es)
MX (1) MX2015012886A (es)
MY (1) MY194727A (es)
NZ (1) NZ712745A (es)
PH (1) PH12015502012A1 (es)
PL (1) PL2970088T3 (es)
PT (1) PT2970088T (es)
SG (1) SG11201507274PA (es)
TW (2) TWI742541B (es)
UY (1) UY35401A (es)
WO (1) WO2014138907A1 (es)
ZA (1) ZA201507062B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
WO2014113388A1 (en) 2013-01-15 2014-07-24 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
DK3203999T3 (da) * 2014-10-10 2020-03-30 Liminal Biosciences Ltd Substituerede aromatiske forbindelser og farmaceutiske sammensætninger til forebyggelse og behandling af osteoporose
CA2967499C (en) 2014-11-12 2023-01-17 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US10046007B2 (en) * 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN111343986A (zh) * 2017-11-15 2020-06-26 加拉帕戈斯股份有限公司 用于治疗纤维化疾病的化合物及其药物组合物
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019231281A1 (ko) * 2018-05-31 2019-12-05 재단법인 아산사회복지재단 폐섬유증의 예방 또는 치료를 위한 스테아르산의 용도
CA3121830A1 (en) * 2018-12-05 2020-06-11 Liminal R&D Biosciences Inc. Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
WO2021015218A1 (ja) * 2019-07-24 2021-01-28 国立大学法人九州大学 転写関連因子を標的とする線維化疾患の予防または治療
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
US20220193073A1 (en) * 2020-12-18 2022-06-23 NovMeta Pharma Co., Ltd. Method of treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
MX2011011756A (es) * 2009-05-04 2012-01-25 Prometic Biosciences Inc Sales de acido 3-pentilfenilacetico y usos farmaceuticos.
NZ595978A (en) * 2009-05-04 2013-11-29 Prometic Biosciences Inc Substituted aromatic compounds and pharmaceutical uses thereof
DK2632452T3 (en) * 2010-10-27 2019-01-21 Prometic Pharma Smt Ltd RELATIONSHIPS AND COMPOSITIONS FOR CANCER TREATMENT
CN102070433B (zh) * 2010-12-27 2013-03-27 桂林师范高等专科学校 芳香基乙酸类衍生物的制备方法
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
CA2967499C (en) * 2014-11-12 2023-01-17 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration

Also Published As

Publication number Publication date
PL2970088T3 (pl) 2020-11-02
JP2016510769A (ja) 2016-04-11
AU2014231649C1 (en) 2018-08-23
DK2970088T3 (da) 2020-03-30
EP2970088A1 (en) 2016-01-20
UY35401A (es) 2014-10-31
MY194727A (en) 2022-12-15
MX2015012886A (es) 2016-04-04
ES2780825T3 (es) 2020-08-27
CA2905633A1 (en) 2014-09-18
HK1220439A1 (zh) 2017-05-05
EP2970088B1 (en) 2020-01-01
AU2014231649B2 (en) 2018-01-04
IL241164A0 (en) 2015-11-30
CN105143170B (zh) 2019-11-08
ZA201507062B (en) 2017-04-26
US20180134649A1 (en) 2018-05-17
US20160023983A1 (en) 2016-01-28
TWI742541B (zh) 2021-10-11
EA201591774A1 (ru) 2015-12-30
KR20160040452A (ko) 2016-04-14
CN105143170A (zh) 2015-12-09
IL241164B (en) 2020-11-30
US9884802B2 (en) 2018-02-06
PH12015502012A1 (en) 2016-01-11
WO2014138907A1 (en) 2014-09-18
US20200017432A1 (en) 2020-01-16
AU2014231649A1 (en) 2015-10-22
EP2970088A4 (en) 2016-10-19
US10450258B2 (en) 2019-10-22
TW201441185A (zh) 2014-11-01
TWI689489B (zh) 2020-04-01
TW202045469A (zh) 2020-12-16
EA031511B1 (ru) 2019-01-31
PT2970088T (pt) 2020-03-27
SG11201507274PA (en) 2015-10-29
BR112015023129A2 (pt) 2017-07-18
JP6381557B2 (ja) 2018-08-29
NZ712745A (en) 2020-06-26
US11267779B2 (en) 2022-03-08
KR102303493B1 (ko) 2021-09-16
CL2015002725A1 (es) 2016-04-15
CA2905633C (en) 2021-12-28

Similar Documents

Publication Publication Date Title
AR095427A1 (es) Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca
AR095429A1 (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
RU2017123878A (ru) Пиколинамидные соединения с фунгицидной активностью
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
CU20160097A7 (es) Compuestos de imidazopirazina como inhibidores de syk
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
AR102362A1 (es) Compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
AR077629A1 (es) Mimetico de smac
AR100006A1 (es) Derivados de tubulisina
JP2012506389A5 (es)
AR098522A1 (es) Compuesto de triazolo-piridina
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
AR093937A1 (es) Compuestos quimicos
BR112013021941A2 (pt) agente terapêutico para tumor
AR092971A1 (es) Inhibidores de agrecanasa
CO2021002768A2 (es) Compuestos de 2,6-diaminopiridina
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
AR097773A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
AR084883A1 (es) Derivados de 2-metoxi-piridin-4-ilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure